Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00373256 · ClinicalTrials.gov registry record · Phase 3
A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer
A Phase 3 study of Breast Neoplasms, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 488
- Enrollment target
- 20
- Study locations
NCT00373256: Completed Phase 3 study of Breast Neoplasms, sponsored by Pfizer.
NCT00373256 is a Phase 3 study of Breast Neoplasms that has completed, run by Pfizer. The registered enrollment target is 488 participants, below the 564-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (13% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00373256, a Phase 3 study of Breast Neoplasms, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 488 participants
- Enrollment target
- 20
- Study locations
Study Summary
To compare treatment with SU011248 plus paclitaxel versus bevacizumab plus paclitaxel to determine which treatment works better against breast cancer
Primary Outcome
Time from date of randomization to the date of the first documentation of objective tumor progression or death due to any cause, whichever occurred first. PFS = (first event date minus randomization date +1) divided by 30.4
Conditions Studied
Interventions
- DRUG Sunitinib
- DRUG bevacizumab
- DRUG paclitaxel
Study Locations (20)
Alabama
- Pfizer Investigational Site - Bessemer
- Pfizer Investigational Site - Birmingham
- Pfizer Investigational Site - Birmingham
- Pfizer Investigational Site - Birmingham
- Pfizer Investigational Site - Birmingham
- Pfizer Investigational Site - Birmingham
- Pfizer Investigational Site - Daphne
- Pfizer Investigational Site - Mobile
- Pfizer Investigational Site - Mobile
California
- Pfizer Investigational Site - Anaheim
- Pfizer Investigational Site - Antioch
- Pfizer Investigational Site - Antioch
- Pfizer Investigational Site - Baldwin Park
- Pfizer Investigational Site - Bellflower
- Pfizer Investigational Site - Fontana
- Pfizer Investigational Site - Fountain Valley
- Pfizer Investigational Site - Gilroy
Arizona
- Pfizer Investigational Site - Flagstaff
- Pfizer Investigational Site - Sedona
Arkansas
- Pfizer Investigational Site - Hot Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 488 participants |
| Start Date | 2006-11 |
| Est. Completion | 2011-08 |
| Phase | Phase 3 |
What the finished NCT00373256 record still lists
NCT00373256 is an interventional study that assigns participants to a tested intervention. The registered 488 participants enrollment target is mid-sized for trials with a published cap, below the 564-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (13% lower).
The record links to 1 condition, with Breast Neoplasms appearing as the primary indexed condition, and to 3 interventions - of which Sunitinib is the first listed.
NCT00373256 names 20 study sites across 4 states, led by Alabama, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT00373256 about?
NCT00373256 is a clinical study titled "A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer". To compare treatment with SU011248 plus paclitaxel versus bevacizumab plus paclitaxel to determine which treatment works better against breast cancer
What is the current status of trial NCT00373256?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 488 participants. The study started on 2006-11. Estimated completion is 2011-08.
What conditions does trial NCT00373256 study?
This clinical trial studies the following conditions: Breast Neoplasms.
What interventions are being tested in trial NCT00373256?
The interventions under investigation include: Sunitinib (DRUG), bevacizumab (DRUG), paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00373256?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00373256 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00373256's enrollment target sits among peer trials
488 23rd of 97 higher than 75 of 97 other Breast Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
RECRUITING · Phase 3
-
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RECRUITING · Phase 3
-
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
RECRUITING · Phase 3
-
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
RECRUITING · Phase 3
-
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
RECRUITING · Phase 3
-
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05154669 · 488 participants · Phase 3
Integrating Financial Coaching and Smoking Cessation Coaching
- NCT06532877 · 488 participants · NA
Telephone Support in Advanced Gastrointestinal Cancer
- NCT06602479 · 488 participants · Phase 2
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
- NCT06794983 · 488 participants · NA
Calls and Coordination for Transitions of Care at Re-entry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia